PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AgeX Therapeutics, Inc. (AGE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00848H1086
CUSIP00848H108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$27.76M
EPS-$482.53
Revenue (TTM)$142.00K
Gross Profit (TTM)$125.00K
EBITDA (TTM)-$9.83M
Year Range$10.91 - $35.20
Target Price$6.50
Short %0.01%
Short Ratio3.88

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AgeX Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AgeX Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17Mar 24
-88.36%
90.06%
AGE (AgeX Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A11.56%
1 monthN/A7.13%
6 monthsN/A17.26%
1 yearN/A26.92%
5 years (annualized)N/A13.56%
10 years (annualized)N/A10.87%

Monthly Returns

The table below presents the monthly returns of AGE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20246.49%-7.07%-18.09%
202335.89%-21.33%12.37%-12.52%-13.79%78.64%-18.27%4.11%-10.53%-11.76%-38.83%4.90%-30.24%
2022-26.36%-14.64%24.64%0.76%-15.78%-20.49%22.87%-19.49%-1.47%6.84%-6.67%-1.45%-49.37%
202114.47%15.52%-19.40%-14.81%-7.97%22.05%-12.90%-23.70%-8.74%-13.82%-13.60%55.74%-28.29%
2020-24.73%-16.06%-19.13%-9.23%33.85%-16.22%11.97%-16.68%-8.29%96.30%11.32%-14.12%-16.48%
201929.43%9.82%-4.71%12.59%-38.38%30.60%-20.16%-7.17%-27.94%-20.41%-8.97%28.17%-39.13%
201899.26%-44.63%10.33%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AGE is 23, indicating that it is in the bottom 23% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of AGE is 2323
AGE (AgeX Therapeutics, Inc.)
The Sharpe Ratio Rank of AGE is 2525Sharpe Ratio Rank
The Sortino Ratio Rank of AGE is 3030Sortino Ratio Rank
The Omega Ratio Rank of AGE is 3131Omega Ratio Rank
The Calmar Ratio Rank of AGE is 1818Calmar Ratio Rank
The Martin Ratio Rank of AGE is 99Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AgeX Therapeutics, Inc. (AGE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AGE
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

There is not enough data available to calculate the Sharpe ratio for AgeX Therapeutics, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17Mar 24
-0.48
2.69
AGE (AgeX Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AgeX Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17Mar 24
-94.27%
-0.72%
AGE (AgeX Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AgeX Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AgeX Therapeutics, Inc. was 94.27%, occurring on Mar 26, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.27%Dec 4, 20181335Mar 26, 2024

Volatility

Volatility Chart

The current AgeX Therapeutics, Inc. volatility is 57.08%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17Mar 24
57.08%
2.72%
AGE (AgeX Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AgeX Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items